The Biomedical Advanced Research and Development Authority, a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, will provide Merck with $268.8 million to adapt and make available multiple existing manufacturing facilities to produce SARS-CoV-2/COVID-19 vaccines and medicines.

Also, Merck signed a deal with Janssen Pharmaceuticals. Merck will support the manufacturing and supply of the Janssen COVID-19 vaccine. Merck will use its facilities in the U.S. to produce drug substance, formulate, and fill vials of Janssen's vaccine.

Merck to acquire Pandion for $1.85B
Merck has announced that it will acquire Pandion Therapeutics for $1.85 billion.

Starpharma, Merck collaborate on new ADCs
Starpharma has signed a research agreement with Merck to conduct preclinical research on dendrimer-based antibody-drug conjugates (ADCs) utilizing Starpharma's...

Artiva, Merck to develop CAR NK cell therapies
Artiva Biotherapeutics and Merck have signed an agreement to develop chimeric antigen receptor (CAR) natural killer (NK) cell therapeutics for solid tumors.

Merck discontinues work on COVID-19 vaccines to focus on therapeutics
Merck will discontinue development of its COVID-19 vaccine candidates because they produced a lower immune response compared to natural infection or other...

Janux, Merck partner on T-cell engager immunotherapies
Janux Therapeutics has entered into a strategic collaboration and licensing agreement with Merck to discover, develop, and commercialize next-generation...